Bioceltix SA announces the success of a clinical trial of a product for atopic dermatitis in dogs. The company is one step closer to registering a breakthrough drug.

A veterinary biotech company listed on the Warsaw Stock Exchange (GPW) has published the final results of a clinical trial of BCX-CM-AD for atopic dermatitis (AD) in dogs. These confirm the safety and effectiveness of Bioceltix’s cell therapy in the short, medium, and long term. A single administration of the drug significantly alleviated skin lesions […]